PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiaries